Overview

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment o

Status:
Not yet recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel

Phase:

Phase 4

Details

Lead Sponsor:

Kovach Eye Institute

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Prednisone